BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32675324)

  • 1. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis.
    Szulzewsky F; Arora S; Hoellerbauer P; King C; Nathan E; Chan M; Cimino PJ; Ozawa T; Kawauchi D; Pajtler KW; Gilbertson RJ; Paddison PJ; Vasioukhin V; Gujral TS; Holland EC
    Genes Dev; 2020 Aug; 34(15-16):1051-1064. PubMed ID: 32675324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis.
    Pajtler KW; Wei Y; Okonechnikov K; Silva PBG; Vouri M; Zhang L; Brabetz S; Sieber L; Gulley M; Mauermann M; Wedig T; Mack N; Imamura Kawasawa Y; Sharma T; Zuckermann M; Andreiuolo F; Holland E; Maass K; Körkel-Qu H; Liu HK; Sahm F; Capper D; Bunt J; Richards LJ; Jones DTW; Korshunov A; Chavez L; Lichter P; Hoshino M; Pfister SM; Kool M; Li W; Kawauchi D
    Nat Commun; 2019 Sep; 10(1):3914. PubMed ID: 31477715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
    Sekine S; Kiyono T; Ryo E; Ogawa R; Wakai S; Ichikawa H; Suzuki K; Arai S; Tsuta K; Ishida M; Sasajima Y; Goshima N; Yamazaki N; Mori T
    J Clin Invest; 2019 May; 129(9):3827-3832. PubMed ID: 31145701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes.
    Takadera M; Satomi K; Szulzewsky F; Cimino PJ; Holland EC; Yamamoto T; Ichimura K; Ozawa T
    Acta Neuropathol Commun; 2020 Nov; 8(1):203. PubMed ID: 33228790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.
    Szulzewsky F; Holland EC; Vasioukhin V
    Dev Biol; 2021 Jul; 475():205-221. PubMed ID: 33428889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis.
    Hu X; Wu X; Berry K; Zhao C; Xin D; Ogurek S; Liu X; Zhang L; Luo Z; Sakabe M; Trubicka J; Łastowska M; Szulzewsky F; Holland EC; Lee L; Hu M; Xin M; Lu QR
    Nat Cell Biol; 2023 Feb; 25(2):323-336. PubMed ID: 36732631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling YAP fusions: a paradigm for investigating rare cancers?
    Sahebjam S; Gilbert MR
    Genes Dev; 2022 Aug; 36(15-16):874-875. PubMed ID: 36207139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis.
    Zhou Y; Zhang J; Li H; Huang T; Wong CC; Wu F; Wu M; Weng N; Liu L; Cheng ASL; Yu J; Wong N; Lo KW; Tang PMK; Kang W; To KF
    Oncogene; 2020 May; 39(22):4375-4389. PubMed ID: 32313226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice.
    Szulzewsky F; Arora S; Arakaki AKS; Sievers P; Almiron Bonnin DA; Paddison PJ; Sahm F; Cimino PJ; Gujral TS; Holland EC
    Genes Dev; 2022 Aug; 36(13-14):857-70. PubMed ID: 36008139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.
    Lamar JM; Stern P; Liu H; Schindler JW; Jiang ZG; Hynes RO
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2441-50. PubMed ID: 22891335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E
    Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ
    Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
    Vlahov N; Scrace S; Soto MS; Grawenda AM; Bradley L; Pankova D; Papaspyropoulos A; Yee KS; Buffa F; Goding CR; Timpson P; Sibson N; O'Neill E
    Curr Biol; 2015 Dec; 25(23):3019-34. PubMed ID: 26549256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer.
    Liu M; Zhang Y; Yang J; Zhan H; Zhou Z; Jiang Y; Shi X; Fan X; Zhang J; Luo W; Fung KA; Xu C; Bronze MS; Houchen CW; Li M
    Gastroenterology; 2021 Apr; 160(5):1771-1783.e1. PubMed ID: 33421513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.